Dicumarol: Difference between revisions

Jump to navigation Jump to search
m (Protected "Dicumarol": Robot: Protecting all pages from category Drug ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Line 28: Line 28:
{{CMG}}
{{CMG}}


{{Editor Help}}
 


===[[Dicumarol (patient information)|For patient information, click here]]===
===[[Dicumarol (patient information)|For patient information, click here]]===
Line 47: Line 47:
[[Category:Drug]]
[[Category:Drug]]
[[Category:Cardiology]]
[[Category:Cardiology]]
{{SIB}}
 
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 00:44, 9 August 2012

Dicumarol
Clinical data
ATC code
Pharmacokinetic data
Protein bindingplasmatic proteins
Metabolismhepatic
Excretionfaeces, urine
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H12O6
Molar mass336.295 g/mol

WikiDoc Resources for Dicumarol

Articles

Most recent articles on Dicumarol

Most cited articles on Dicumarol

Review articles on Dicumarol

Articles on Dicumarol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Dicumarol

Images of Dicumarol

Photos of Dicumarol

Podcasts & MP3s on Dicumarol

Videos on Dicumarol

Evidence Based Medicine

Cochrane Collaboration on Dicumarol

Bandolier on Dicumarol

TRIP on Dicumarol

Clinical Trials

Ongoing Trials on Dicumarol at Clinical Trials.gov

Trial results on Dicumarol

Clinical Trials on Dicumarol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dicumarol

NICE Guidance on Dicumarol

NHS PRODIGY Guidance

FDA on Dicumarol

CDC on Dicumarol

Books

Books on Dicumarol

News

Dicumarol in the news

Be alerted to news on Dicumarol

News trends on Dicumarol

Commentary

Blogs on Dicumarol

Definitions

Definitions of Dicumarol

Patient Resources / Community

Patient resources on Dicumarol

Discussion groups on Dicumarol

Patient Handouts on Dicumarol

Directions to Hospitals Treating Dicumarol

Risk calculators and risk factors for Dicumarol

Healthcare Provider Resources

Symptoms of Dicumarol

Causes & Risk Factors for Dicumarol

Diagnostic studies for Dicumarol

Treatment of Dicumarol

Continuing Medical Education (CME)

CME Programs on Dicumarol

International

Dicumarol en Espanol

Dicumarol en Francais

Business

Dicumarol in the Marketplace

Patents on Dicumarol

Experimental / Informatics

List of terms related to Dicumarol

Cardiology Network

Discuss Dicumarol further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


For patient information, click here

Dicumarol (or Dicoumarol) is an anticoagulant that functions by as a Vitamin K antagonist (similar to warfarin).

It is a derivative of coumarin.

External links

  • Template:DiseasesDB
  • Cullen J, Hinkhouse M, Grady M, Gaut A, Liu J, Zhang Y, Weydert C, Domann F, Oberley L (2003). "Dicumarol inhibition of NADPH: quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism". Cancer Res. 63 (17): 5513–20. PMID 14500388.
  • Mironov A, Colanzi A, Polishchuk R, Beznoussenko G, Mironov A, Fusella A, Di Tullio G, Silletta M, Corda D, De Matteis M, Luini A (2004). "Dicumarol, an inhibitor of ADP-ribosylation of CtBP3/BARS, fragments golgi non-compact tubular zones and inhibits intra-golgi transport". Eur J Cell Biol. 83 (6): 263–79. PMID 15511084.
  • Abdelmohsen K, Stuhlmann D, Daubrawa F, Klotz L (2005). "Dicumarol is a potent reversible inhibitor of gap junctional intercellular communication". Arch Biochem Biophys. 434 (2): 241–7. PMID 15639223.
  • Thanos C, Liu Z, Reineke J, Edwards E, Mathiowitz E (2003). "Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride". Pharm Res. 20 (7): 1093–100. PMID 12880296.



Template:WikiDoc Sources